Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Maintenance After Tandem Auto-Allo Transplant in Multiple Myeloma
NCT01264315Phase 2Completed
- Sponsor
- Fondazione EMN Italy
- Start
- Sep 2008
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoint: Lenalidomide toxicity and tolerability after allografting at 6 years. Started Sep 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01264315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01264315.